China
Africa
Explore chapters and articles related to this topic
Triclabendazole
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Triclabendazole is a benzimidazole carbamate anthelmintic that was originally synthesized by Ciba-Geigy, now Novartis. It was initially developed as a veterinary anthelmintic and was first used for the treatment of human fascioliasis in 1986 (Wessely et al., 1988). The use of triclabendazole was expanded in Iran in 1989 during an epidemic of fascioliasis near the Caspian Sea, where studies demonstrated its tolerability and superior efficacy over other agents. In 1990, the Division of Control of Tropical Diseases (CTD) of the World Health Organization (WHO) and the pharmaceutical company Ciba-Geigy concluded a Memorandum of Understanding to conduct additional clinical trials of triclabendazole for the treatment of fascioliasis and paragonimiasis. In 1997, based on the remarkable success of these trials, the WHO Expert Committee on the Use of Essential Drugs recommended that the drug be included in the Essential Drugs List (WHO, 1998a). The process of registering triclabendazole for human use is under way in countries where fascioliasis is endemic (first registered in Egypt in 2000). It is currently marketed as Egaten/Fasinex by the originators.
Paragonimus westermani
Published in Eric S. Loker, Bruce V. Hofkin, Parasitology, 2015
Eric S. Loker, Bruce V. Hofkin
Treatment The drug of choice is praziquantel. Bithionol is also effective but requires extended treatment. Triclabendazole has been used successfully and may have an advantage in areas where fascioliasis is also present. (Fasciola responds to triclabendazole but not praziquantel.)
Identification of suspected paragonimiasis-endemic foci using a questionnaire and detection of Paragonimus ova using the Ziehl–Neelsen technique in Zamboanga Region, the Philippines
Published in Pathogens and Global Health, 2020
John Paul Caesar delos Trinos, Olivia T Sison, Maria Reiza C Anino, Jana Denise M. Lacuna, Manuel C. Jorge, Vicente Y. Belizario
Areas such as Libato in Tambulig, which had the highest paragonimiasis prevalence, may require other prevention and control strategies, such as mass drug administration (MDA). WHO recommends MDA of triclabendazole (20 mg/kg) for areas that are highly endemic for paragonimiasis (reference). The challenge, however, is that no threshold for highly endemic areas and MDA guidelines, in general, have been established [5]. Moreover, the DOH still uses praziquantel for the treatment of paragonimiasis, as of project implementation. MDA of triclabendazole has been shown to be safe and effective in controlling fascioliasis [15]. The experience in MDA of triclabendazole for fascioliasis control may be a guide in assessing the effect of MDA of triclabendazole for paragonimiasis control.
Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures
Published in Expert Review of Anti-infective Therapy, 2021
Luis Marcos, Vicente Maco, Angelica Terashima
In addition, there is an urgent need for new clinical trials using new regimens of TCBZ. Currently, one study is ongoing titled ‘A Phase IV, Multi-center, Open-label Study to Determine the Safety, Tolerability, and Clinical Outcomes Following Oral Administration of Triclabendazole in Patients (6 Years of Age or Older) With Fascioliasis’ to assess tolerability of TCBZ using two 10 mg/kg doses given 12 hours apart (available at ClinicalTrials.gov Identifier: NCT04230148). However, no studies have assessed the tolerability and efficacy of higher doses of TCBZ in human fascioliasis, and are likely needed due to the current presence of treatment failures with TCBZ seen in clinical practice in endemic areas.
Oxfendazole: a promising agent for the treatment and control of helminth infections in humans
Published in Expert Review of Anti-infective Therapy, 2019
Armando E. Gonzalez, Ellen E. Codd, John Horton, Hector H. Garcia, Robert H. Gilman
In a comparative study aimed to assess the efficacy of triclabendazole, 18 naturally infected cysticercosis pigs were treated orally with triclabendazole (single dose, 30 mg/kg, n = 6), OXF (single dose, 30 mg/kg, n = 6), or placebo (control group, n = 6), and euthanized 17 weeks later. OXF-treated pigs had only degenerated cysts in their carcasses, whereas triclabendazole had very little effect [16].